Показатели перекисного окисления липидов и системы антиоксидантной защиты у больных псориазом и ишемической болезнью сердца при комплексном лечении с мексикором
М. А. Парфенова, И. И. Бобынцев, Л. В. Силина · Курский научно-практический вестник "Человек и его здоровье" · 2012
The combined therapy with Mexicor was used in psoriasis patients with different clinical forms of psoriatic disease in the stage of progression in combination with stable FC II-III angina. The introduction of Mexicor in the standard patients’ treatment contributed to the significantly greater reduction of lipid peroxidation products (malondialdehyde, acetyl hydroperoxide) in patients’ blood serum than in those receiving only standard therapy, against the background of more expressed clinical symptoms regression, measured according to the PASI index (Psoriasis Arca and Severity Index). Antioxidant blood factors (catalase, superoxide dismutase, total antioxidant activity) in the studied groups of patients did not differ significantly.
Cited by 0 works.